Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 25;1:100007. doi: 10.1016/j.conx.2019.100007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 4 — Impairment of sperm membrane integrity by tideglusib.

(A–D) Evaluation of sperm membrane integrity using HOS assays and (E–H) SYBR-14/PI staining. HOS assays of (A) intact (blank control), (B) N-9 treatment (at 1 × MEC, approx. 260 μM for 20 s) and (C) tideglusib treatment (10 μM for 20 s) on human sperm. (D) Percentage of HOS-positive sperms after treatment with N-9 or tideglusib at MECs for 20 s or blank control. Data are expressed as percentage (%) of total sperm counts. CN: blank control; **p <.01. (E–H) SYBR-14/PI staining and flow cytometry analysis. (E) Blank control. (F) N-9 treatment (260 μM) for 20 s. (G) Tideglusib treatment (1.25 μM) for 60 min. (H) Tideglusib treatment (10 μM) for 20 s.